Perspective Therapeutics, Inc.CATXNYSE
Loading
Year-over-year research & development expense growth
Percentile
P90
Near historical high
vs 2Y Ago
9.9x
Strong expansion
Streak
1 qtr
Consecutive declineStable
| Period | Value |
|---|---|
| Q4 2025 | 61.88% |
| Q3 2025 | 67.07% |
| Q2 2025 | -15.06% |
| Q1 2025 | 11.25% |
| Q4 2024 | 7.11% |
| Q3 2024 | 29.68% |
| Q2 2024 | 24.46% |
| Q1 2024 | 22.57% |
| Q4 2023 | 6.28% |
| Q3 2023 | 1.20% |
| Q2 2023 | 46.56% |
| Q1 2023 | 529.20% |
| Q4 2022 | -13.42% |
| Q3 2022 | -11.06% |
| Q2 2022 | 44.99% |
| Q1 2022 | 2.62% |
| Q4 2021 | -23.79% |
| Q3 2021 | 50.00% |
| Q2 2021 | 29.28% |
| Q1 2021 | 27.02% |
| Q4 2020 | -8.65% |
| Q3 2020 | -3.11% |
| Q2 2020 | 9.52% |
| Q1 2020 | 6.14% |
| Q4 2019 | 18.88% |
| Q3 2019 | -31.67% |
| Q2 2019 | 14.05% |
| Q1 2019 | -27.78% |
| Q4 2018 | -1.43% |
| Q3 2018 | -26.57% |
| Q2 2018 | 20.93% |
| Q1 2018 | 39.12% |
| Q4 2017 | -6.08% |
| Q3 2017 | 14.56% |
| Q2 2017 | -3.36% |
| Q1 2017 | 118.00% |
| Q4 2016 | -12.79% |
| Q3 2016 | 20.51% |
| Q2 2016 | -22.09% |
| Q1 2016 | 214.57% |